Details for Patent: 9,303,051

Which drugs does patent 9,303,051 protect, and when does it expire?

Patent 9,303,051 protects TEMBEXA and is included in two NDAs.

This patent has nineteen patent family members in ten countries.

Summary for Patent: 9,303,051

Title:	Phosphonate ester derivatives and methods of synthesis thereof
Abstract:	The disclosure describes methods of synthesis of phosphonate ester derivatives. Preferred methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of phosphonate ester derivatives without the use of chromatographic purification methods and in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of phosphonate ester derivatives.
Inventor(s):	Ware; Roy W. (Raleigh, NC), Almond; Merrick R. (Apex, NC), Lampert; Bernhard M. (Rougemont, NC)
Assignee:	Chimerix Inc. (Durham, NC)
Application Number:	14/808,388
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 9,303,051

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emergent Biodefense	TEMBEXA	brincidofovir	SUSPENSION;ORAL	214460-001	Jun 4, 2021		RX	Yes	Yes			Y	Y		METHOD OF TREATING HUMAN SMALLPOX DISEASE
Emergent Biodefense	TEMBEXA	brincidofovir	TABLET;ORAL	214461-001	Jun 4, 2021		RX	Yes	Yes			Y	Y		METHOD OF TREATING HUMAN SMALLPOX DISEASE

International Family Members for US Patent 9,303,051

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011295937
Brazil	112013004925
Canada	2809679
China	103209985